Stephen Ray Mitchell
Known title: DirectorCIK: 0001802653
Associated companies
Transaction History
| VNDA | ▲ Buy | Grant | 41,600 | $0 | 6/4/2026 | View on chart |
| VNDA | ▼ Sell | Gift | 25,836 | $0 | 5/18/2026 | View on chart |
| VNDA | ▼ Sell | Open Market | 7,000 | $32K | 6/13/2025 | View on chart |
| VNDA | ▲ Buy | Grant | 59,225 | $0 | 6/5/2025 | View on chart |
| VNDA | ▼ Sell | Open Market | 5,000 | $26K | 11/14/2024 | View on chart |
| VNDA | ▲ Buy | Grant | 20,529 | $0 | 5/17/2024 | View on chart |
| VNDA | ▼ Sell | Open Market | 6,500 | $39K | 8/10/2023 | View on chart |
| VNDA | ▲ Buy | Grant | 17,307 | $0 | 6/8/2023 | View on chart |
| VNDA | ▲ Buy | Grant | 12,006 | $0 | 6/16/2022 | View on chart |
| VNDA | ▼ Sell | Open Market | 2,700 | $26K | 6/13/2022 | View on chart |
| VNDA | ▲ Buy | Option Exercise | 5,985 | $63K | 9/9/2021 | View on chart |
| VNDA | ▲ Buy | Option Exercise | 13,124 | $167K | 9/9/2021 | View on chart |
| VNDA | ▼ Sell | Open Market | 19,109 | $320K | 9/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Oppenheimer Launches Coverage on Vanda Pharmaceuticals
Oppenheimer has begun covering Vanda Pharmaceuticals, issuing an outperform rating and a $10 price target. The target sits near the middle of the analyst range and below the 52‑week high, suggesting a cautious upside view. The stock is trading above its $5.21 support level with an RSI of 41.6, indicating room for movement.
Oppenheimer Launches Coverage on Vanda Pharmaceuticals. Oppenheimer has begun covering Vanda Pharmaceuticals, issuing an outperform rating and a $10 price target. The target sits near the middle of the analyst range and below the 52‑week high, suggesting a cautious upside view. The stock is trading above its $5.21 support level with an RSI of 41.6, indicating room for movement.